Effects of anti-thrombotic drugs on all-cause mortality after upper gastrointestinal bleeding in Japan: A multicenter study with 2205 cases.
anti-thrombotics
mortality rate
upper gastrointestinal bleeding
Journal
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
ISSN: 1443-1661
Titre abrégé: Dig Endosc
Pays: Australia
ID NLM: 9101419
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
09
12
2020
accepted:
16
02
2021
pubmed:
23
2
2021
medline:
14
1
2022
entrez:
22
2
2021
Statut:
ppublish
Résumé
Although anti-thrombotic use is recognized as a risk factor for upper gastrointestinal bleeding (UGIB), there has been no clear evidence that it worsens the outcomes after the bleeding. The aim of this study is to investigate the effects of anti-thrombotic agents on in-hospital mortality following UGIB. Information on clinical parameters, including usage of anti-thrombotic agents, was retrospectively collected from consecutive patients with UGIB at 12 high-volume centers in Japan between 2011 and 2018. The all-cause in-hospital mortality rate was evaluated according to the usage of anti-thrombotic agents. Clinical data were collected from 2205 patients with endoscopically confirmed UGIB. Six hundred and forty-five (29.3%) patients used anti-thrombotic agents. The all-cause in-hospital mortality rate was 5.7% (125 deaths). After excluding 29 cases in which death occurred due to end-stage malignancy, 96 deaths (bleeding-related, n = 22 ; non-bleeding-related, n = 74) were considered "preventable." Overall, the "preventable" mortality rate in anti-thrombotic users was significantly higher than that in non-users (6.0% vs. 3.7%, P < 0.05). However, the "preventable" mortality of anti-thrombotic users showed a marked improvement over time; although the rate in users remained significantly higher than that in non-users until 2015 (7.3% vs. 4.2%, P < 0.05), after 2016, the difference was no longer statistically significant (4.8% vs. 3.5%). Although the usage of anti-thrombotic agents worsened the outcomes after UGIB, the situation has recently been improving. We speculate that the recent revision of the Japanese guidelines on the management of anti-thrombotic treatment after UGIB may have partly contributed to improving the survival of users of anti-thrombotic agents.
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-122Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Japan Gastroenterological Endoscopy Society.
Références
Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: A nationwide analysis. Gastrointest Endosc 2015; 81: 882-8.
van Leerdam ME, Vreeburg EM, Rauws EA et al. Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003; 98: 1494-9.
Taefi A, Cho WK, Nouraie M. Decreasing trend of upper gastrointestinal bleeding mortality risk over three decades. Dig Dis Sci 2013; 58: 2940-8.
Sung JJ, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW. Causes of mortality in patients with peptic ulcer bleeding: A prospective cohort study of 10,428 cases. Am J Gastroenterol 2010; 105: 84-9.
Lanas A, García-Rodríguez LA, Polo-Tomás M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 1633-41.
Jimenez-Rosales R, Valverde-Lopez F, Vadillo-Calles F, Martinez-Cara JG, Lopez de Hierro M, Redondo-Cerezo E. Inhospital and delayed mortality after upper gastrointestinal bleeding: An analysis of risk factors in a prospective series. Scand J Gastroenterol 2018; 53: 714-20.
Nahon S, Nouel O, Hagege H et al. Favorable prognosis of upper-gastrointestinal bleeding in 1041 older patients: Results of a prospective multicenter study. Clin Gastroenterol Hepatol 2008; 6: 886-92.
Fujishiro M, Iguchi M, Kakushima N et al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig Endosc 2016; 28: 363-78.
Horibe M, Iwasaki E, Bazerbachi F et al. Horibe GI bleeding prediction score: A simple score for triage decision-making in patients with suspected upper GI bleeding. Gastrointest Endosc 2020; 92: 578-88.
Horibe M, Ogura Y, Matsuzaki J et al. Absence of high-risk stigmata predicts good prognosis even in severely anemic patients with suspected acute upper gastrointestinal bleeding. United European Gastroenterol J 2018; 6: 684-90.
Fukuda S, Shimodaira Y, Watanabe K et al. Risks for rebleeding and in-hospital mortality after gastrointestinal bleeding in a tertiary referral center in Japan. Digestion 2020; 101: 31-7.
Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: 2354-94.
Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13: 906-12.
Iijima K, Shimosegawa T. Risk factors for upper GI damage in low-dose aspirin users and the interaction between H. pylori infection and low-dose aspirin use. Curr Pharm Des 2015; 21: 5056-65.
Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. BMJ 2019; 364: l536.
Fujimoto K, Fujishiro M, Kato M et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014; 26: 1-14.
Satoh K, Yoshino J, Akamatsu T et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol 2016; 51: 177-94.
Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318-21.
Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011; 74: 1215-24.
Iino C, Mikami T, Igarashi T et al. Evaluation of scoring models for identifying the need for therapeutic intervention of upper gastrointestinal bleeding: A new prediction score model for Japanese patients. Dig Endosc 2016; 28: 714-21.
Masaoka T, Suzuki H, Hori S, Aikawa N, Hibi T. Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention. J Gastroenterol Hepatol 2007; 22: 1404-8.
Kondo Y, Hatta W, Koike T et al. The use of higher dose steroids increases the risk of rebleeding after endoscopic hemostasis for peptic ulcer bleeding. Dig Dis Sci 2018; 63: 3033-40.
Nakamura S, Matsumoto T, Sugimori H, Esaki M, Kitazono T, Hashizume M. Emergency endoscopy for acute gastrointestinal bleeding: Prognostic value of endoscopic hemostasis and the AIMS65 score in Japanese patients. Dig Endosc 2014; 26: 369-76.
Abougergi MS, Charpentier JP, Bethea E et al. A prospective, multicenter study of the AIMS65 score compared with the Glasgow-Blatchford score in predicting upper gastrointestinal hemorrhage Outcomes. J Clin Gastroenterol 2016; 50: 464-9.
Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: Patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-35.
Dunne PDJ, Laursen SB, Laine L et al. Previous use of antithrombotic agents reduces mortality and length of hospital stay in patients with high-risk upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2019; 17: 440-7.
Ara N, Iijima K, Maejima R et al. Prospective analysis of risk for bleeding after endoscopic biopsy without cessation of antithrombotics in Japan. Dig Endosc 2015; 27: 458-64.
Ahsberg K, Höglund P, Kim WH, von Holstein CS. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010; 45: 1404-15.
Thomopoulos KC, Mimidis KP, Theocharis GJ, Gatopoulou AG, Kartalis GN, Nikolopoulou VN. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: Endoscopic findings, clinical management and outcome. World J Gastroenterol 2005; 11: 1365-8.
Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-21.
Yamashita T, Koretsune Y, Yang Y et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation - an ENGAGE AF-TIMI 48 subanalysis. Circ J 2016; 80: 860-9.
Hori M, Connolly SJ, Zhu J et al. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891-6.
Wong KS, Hu DY, Oomman A et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014; 45: 1739-47.
Sengupta N, Feuerstein JD, Patwardhan VR et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: A prospective study. Am J Gastroenterol 2015; 110: 328-35.
Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Ann Intern Med 2010; 152: 1-9.
Staerk L, Lip GY, Olesen JB et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: Nationwide cohort study. BMJ 2015; 351: h5876.